




Welcome

Giovanni Apolone
Scientific Director INT – Milano
President Elect OECD - Brussels

November 7, 2022

Disclosure



- No economic, financial or personal conflicts of interest
- Scientific Director of INT, a CCC receiving several funds from national and international entities to support institutional studies

OUTLINE

- The European scenario
 - Cancer in Europe EU initiatives: EBCP and CM
- EBCP and CM
- Relevant actions ongoing
- The lessons from COVID19
 - Advancing innovation, open science and data sharing

Cancer in Europe


Epidemiology: 2.7 million new cases (2020), 1.3 million deaths (2020), expected increase of about 25% by 2035

Variability in Epidemiology, Economics and Outcomes

EU INITIATIVES ON CANCER

- Europe Beating Cancer Plan and Cancer Mission have the objectives to reduce mortality, increase survival and ameliorate QoL by
 - increasing knowledge
 - improve quality of care
 - and fighting unacceptable and actionable variability (inequalities)

ACTIONS ONGOING



Call - Research and Innovation actions supporting the implementation of the Mission on Cancer

HORIZON-MISS-2023-CANCER-01

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR million) ²	Indicative number of projects expected to be funded
		2023		
Opening: 12 Jan 2023 Deadline(s): 12 Apr 2023				
HORIZON-MISS-2023-CANCER-01-01	RIA	36.68 ³	7.00 to 12.00	4
HORIZON-MISS-2023-CANCER-01-02	RIA	25.00 ⁴	4.00 to 6.00	5
HORIZON-MISS-2023-CANCER-01-03	RIA	43.00 ⁵	6.00 to 8.00	7
HORIZON-MISS-2023-CANCER-01-04	IA	6.00 ⁶	Around 6.00	1
Overall indicative budget		110.68		



Publication January 2023

Deadline April 2023

CALL TITLES

HORIZON-MISS-2023-CANCER-01-01: Addressing poorly-understood tumour-host interactions to enhance immune system-centred treatment and care interventions in childhood, adolescent, adult and elderly cancer patients.

HORIZON-MISS-2023-CANCER-01-02: Enhance primary cancer prevention through sustainable behavioural change

HORIZON-MISS-2023-CANCER-01-03: Pragmatic clinical trials on minimally invasive diagnostics

HORIZON-MISS-2023-CANCER-01-04: Establish best practices and tools to improve the quality of life for childhood cancer patients, survivors and their families in European regions

Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs



Nakela L. Cook, MD, MPH, Patient-Centered Outcomes Research Institute and
Michael S. Lauer, MD, National Institutes of Health

July 26, 2021

... emerging stronger after COVID19 ... priorities for
health systems transformation...

FROM THE NAM PAPER

- « ... within weeks the virus was identified and less than 11 months after new vaccines developed...»
- « ... multiple large clinical trials and population based studies were carried out, often in multiple countries»
- «.. new large scale diagnostics were made available ...»
- « ... prior basic science discoveries and infrastructures were repurposed ...»
- « ... Inclusion of participants traditionally under-represented in research ...
- « ... new public-private partnership activated...»

Final reflections

- The ongoing pandemic was a stress test that confirmed weaknesses and revealed fragilities
- The reaction of the scientific community created an advancing in innovation, open science and data sharing in almost all fields
- An important lesson to be traslatted to out fight against cancer